Literature DB >> 18158635

Endometrial thermal balloon ablation has a beneficial long-term effect on menorrhagia.

Sari Ahonkallio1, Hannu Martikainen, Markku Santala.   

Abstract

BACKGROUND: More data on the long-term results of thermal balloon endometrial ablation are needed.
METHODS: A retrospective observational study of 190 women who underwent endometrial thermal balloon ablation in the treatment of menorrhagia. The mean follow-up period was 6 years.
RESULTS: Of the 172 women analysed after exclusion, 28 (16%) had a hysterectomy during follow-up. Women with regular menstrual periods had the best outcome. Some 152 (89%) women filled in a questionnaire concerning their satisfaction with the procedure, and 76% were satisfied. Amenorrhoea was reported by 14% and eumenorrhoea by 54% of the women who completed the questionnaire.
CONCLUSION: Endometrial thermal balloon ablation has good long-term efficacy and can be considered an applicable alternative in the treatment of menorrhagia, especially for women who have regular periods and are over 40 years of age.

Entities:  

Mesh:

Year:  2008        PMID: 18158635     DOI: 10.1080/00016340701797823

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Modified Thermal Balloon Endometrial Ablation for Treatment of Heavy Menstrual Bleeding.

Authors:  Baraa Lukman Humo Al-Ibrahim; Ahmed Jasim Al Husaynei
Journal:  Gynecol Minim Invasive Ther       Date:  2022-05-04

2.  Thermal balloon endometrial ablation in dysfunctional uterine bleeding.

Authors:  Rishma Dhillon Pai
Journal:  J Gynecol Endosc Surg       Date:  2009-01

3.  Thermal balloon endometrial ablation in the treatment of heavy menstrual bleeding.

Authors:  Zinatossadat Bouzari; Shahla Yazdani; Samira Azimi; Mouloud Agajani Delavar
Journal:  Med Arch       Date:  2014-12-16

4.  Cost-Effectiveness of Global Endometrial Ablation vs. Hysterectomy for Treatment of Abnormal Uterine Bleeding: US Commercial and Medicaid Payer Perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Andrea S Lukes; Shannon K Laughlin-Tommaso
Journal:  Popul Health Manag       Date:  2015-02-25       Impact factor: 2.459

5.  CavatermTM plus treatment in high - risk surgical patients.

Authors:  Zinatossadat Bouzari; Ebrahim Alijanpour; Shahla Yazdani; Azita Ghanbarpour; Ali Bijani; Tahereh Ashraf Ganjoei; Hemmat Gholinia
Journal:  Caspian J Intern Med       Date:  2021-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.